Hims & Hers Health (NYSE:HIMS) Insider Sells $467,128.05 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Deborah Autor sold 16,773 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider owned 48,961 shares in the company, valued at approximately $1,363,563.85. This trade represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Trading Up 5.7%

HIMS stock opened at $33.67 on Friday. The business has a fifty day moving average price of $32.37 and a 200 day moving average price of $26.14. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The stock has a market capitalization of $7.86 billion, a price-to-earnings ratio of -53.44 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.17 EPS. Analysts expect that Hims & Hers Health, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the business. Versant Capital Management Inc boosted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares during the last quarter. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC raised its position in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of research analyst reports. Barclays decreased their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Friday. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research note on Friday, May 22nd. Finally, BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $32.17.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
• Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
• Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
• Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
• Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
• Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.